JAMA Network Home
Sign In
Editorial

Gefurulimab—The First Effective Nanobody in Myasthenia Gravis Therapy

JAMA Neurology 10.1001/jamaneurol.2026.2329

July 27, 2026 at 11:00 AM EDT

Read the full article

Corresponding Author: Ralf Gold, MD, Department of Neurology, Ruhr University Bochum, St. Josef Hospital, Gudrunstrasse 56, Bochum 44791, Germany (ralf.gold@rub.de).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.2329?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=072726

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks